4
NEWS
New patch
pump in
Europe
Diabeloop and EOFlow have
announced that are partnering to
offer the latter's EOPatch system with
automated insulin delivery in Europe.
The partnership combines the
EOPatch, a third-party continuous
glucose monitor (CGM), and
Diabeloop's automated insulin
delivery algorithm - with both
integrating into Diabeloop's currently
under-development smartphone app.
All three components of the
planned automated insulin delivery
system have already received CE
mark in Europe, with Diabeloop
earmarking a commercial launch for
the end of 2023.
"It is an honor to partner with
EOFlow and combine our state-ofthe-art
automated insulin delivery
algorithm with their innovative
wearable insulin pump solution.
Diabeloop and EOFlow share the
same goal to offer choices to people
living with diabetes by providing
advanced and user-friendly
solutions," said Diabeloop co-founder
and CEO Erik Huneker.
Oral insulin update
Oramed Pharmaceuticals has announced that it has received a new patent
for its oral diabetes treatment. The patent covers oral pharmaceutical
compositions comprising insulin in combination with glucagon-like
peptide 1 (GLP-1).
Oramed aims to change the treatment of diabetes with its ORMD-0801
oral insulin capsule. The capsule is currently under evaluation in two pivotal
Phase 3 trials. The company recently inked a deal to commercialize the oral
insulin treatment in the Republic of Korea.
Dexcom
Trends
Dexcom reports another record year
of new customers amid continued
demand for G6 device. Dexcom said
it recorded another record year
of new customer starts in 2022,
bolstered by continued demand for
its G6 continuous glucose monitor.
The maker of diabetes devices
added about 450,000 new users in
2022 for a total of 1.7m customers
globally. Last year in the US, the
Centers for Medicare and Medicaid
Services proposed a local coverage
determination that would expand
access to CGMs for Medicare
patients. It would broaden coverage
to include people with Type 2
diabetes, who only take basal or
daily insulin, as well as some people
who don't use insulin but experience
hypoglycaemia. In 18 months, the
company has added 3.5m more
people whose insurance covers the
device in the US.
While the G7 received a CE
Mark last year in Europe, most of
Dexcom's growth there has been
from expanded coverage of its G6
device. The company's Dexcom One
device, a simpler, less expensive
system that also received European
approval last year, is expected
to account for about a third of
international customer starts in
2023, CFO Jereme Sylvain said.
New SGLT-2
inhibitor
The US Food and Drug
Administration has approved
a new medication for Type 2
diabetes called Brenzavvy. This
belongs to a class of drugs known
as SGLT-2 inhibitors, which work
by helping the body remove
excess glucose (sugar) through
the urine.
Brenzavvy was approved
based on results from 23 clinical
trials, which showed that the
medication effectively lowered
blood sugar levels and improved
overall diabetes control. The most
common side effect of Brenzavvy
was yeast infections.
Brenzavvy, which can be used
alone or in combination with
other diabetes medications, is not
approved for people with Type 1
diabetes.
Brenzavvy is now the fifth
SGLT-2 inhibitor approved in
the US, along with Invokana
(canagliflozin), Farxiga
(dapagliflozin), Jardiance
(empagliflozin), and Steglatro
(ertugliflozin).
To read more CLICK HERE.